Yildirim

Researchers are evaluating the effects of NNC0487-0111 in adults with excess body weight and obstructive sleep apnea who are not using positive airway pressure treatment. This Phase 3 trial aims to assess the safety and effectiveness of this medication in helping participants lose weight and improve their sleep apnea. The study compares NNC0487-0111 with a placebo, which is an inactive treatment given by chance to participants. Participants receive weekly injections of either NNC0487-0111 or a matching placebo under the skin using pre-filled pen injectors applied to the thigh, abdomen, or upper arm. Both groups follow a reduced-calorie diet and increase physical activity during the study. The treatment period lasts for 80 weeks, during which researchers monitor changes in body weight and sleep apnea severity. Throughout the study, participants undergo regular assessments including body weight measurements and evaluation of the apnea-hypopnea index AHI to track sleep apnea severity. Additional tests measure sleep-related impairment, blood pressure, cholesterol levels, and blood sugar control. Safety is monitored by tracking any adverse events during the 84 weeks of the study. Participants progress is carefully followed to understand the impact of the treatment on weight and sleep apnea over time.

Researchers are evaluating the effectiveness and safety of NNC0487-0111 in adults with overweight or obesity who also have obstructive sleep apnoea and are being treated with positive airway pressure. This phase 3 study compares NNC0487-0111 to a placebo, which contains no active medicine, to see how well the treatment helps with weight loss and improvement in sleep apnoea symptoms. Participants will receive one of two dose levels of NNC0487-0111 or a matching placebo as weekly injections under the skin. These injections are given alongside a reduced-calorie diet and increased physical activity. The treatment is administered using pre-filled pen injectors to the thigh, abdomen, or upper arm, and the study lasts for 80 weeks. Throughout the trial, participants will be monitored regularly to assess changes in body weight, sleep apnoea severity measured by the apnoea-hypopnoea index AHI, and other health measures such as waist and neck circumference, blood pressure, cholesterol, blood sugar, and sleep quality scores. Safety is tracked by recording any treatment-related adverse events. The study runs until week 80, with follow-up continuing through week 84 to evaluate ongoing safety and effectiveness.

Researchers are evaluating the safety and effects of NNC0487-0111 in adults with excess body weight and knee osteoarthritis. This study compares the active treatment with a placebo injection given once weekly. The goal is to assess weight loss and pain reduction over a long-term period, as well as other health measures related to osteoarthritis and metabolic health. Participants are randomly assigned to receive one of two dose levels of NNC0487-0111 or a placebo injection, both administered under the skin once a week. These injections are given alongside a reduced-calorie diet and increased physical activity. The treatment period lasts up to 80 weeks, during which participants follow the specified lifestyle changes. Throughout the study, participants will have regular assessments including body weight, knee pain and function scores WOMAC, physical functioning, blood pressure, cholesterol levels, blood sugar control HbA1c and fasting glucose, and use of pain medications. Safety events and adverse reactions are monitored up to week 84. Participants will be followed closely with these measurements to evaluate the treatments impact and overall safety.

Researchers are evaluating whether adding diaphragmatic kinesio taping to high-intensity interval training HIIT improves physical performance in trained adults aged 18 to 35 years. This study focuses on aerobic capacity, anaerobic power, balance, and lung function. It aims to see if supporting breathing muscles with taping enhances the benefits of HIIT beyond training alone. Participants will be randomly assigned to two groups. One group will complete an 8-week HIIT program on a cycle ergometer, training three times per week with intervals targeting 85-95% of maximal heart rate. The other group will follow the same HIIT protocol but will also receive diaphragmatic kinesio taping applied before each session to support breathing muscles. No other training changes are made. Before and after the 8-week program, participants will undergo tests measuring aerobic capacity VO2max, anaerobic performance Wingate test, balance Y-Balance test, lung function, body composition, and heart rate response. These assessments will help understand physiological changes and whether taping offers extra benefits. The study includes supervised training sessions and careful monitoring throughout.